The tumor suppressor ING3 is degraded by SCF Skp2-mediated ubiquitin-proteasome system

Oncogene

Volumn 29, Issue 10, 2010, Pages 1498-1508

  Chen, G ^a   Wang, Y ^a   Garate, M ^a   Zhou, J ^b   Li, G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; ING3; Protein degradation; Skp2

Indexed keywords

F BOX PROTEIN; INHIBITOR OF GROWTH FAMILY MEMBER 3; PROTEASOME; S PHASE KINASE ASSOCIATED PROTEIN 2; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HOMEODOMAIN PROTEINS; HUMANS; LYSINE; MELANOMA; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; S-PHASE KINASE-ASSOCIATED PROTEINS; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; TRANS-ACTIVATORS; UBIQUITIN; UBIQUITINATION; ULTRAVIOLET RAYS;

EID: 77949423402     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.424     Document Type: Article

References (43)

1. Ang XL, Wade Harper J. (2005). SCF-mediated protein degradation and cell cycle control. Oncogene 24: 2860-2870.
2. Asher G, Tsvetkov P, Kahana C, Shaul Y. (2005). A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 19: 316-321.
3. Ben-Shahar S, Komlosh A, Nadav E, Shaked I, Ziv T, Admon A et al. (1999). 26 S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. J Biol Chem 274: 21963-21972.
4. Burger AM, Seth AK. (2004). The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 40: 2217-2229.
5. Chiappetta G, De Marco C, Quintiero A, Califano D, Gherardi S, Malanga D et al. (2007). Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr Relat Cancer 14: 405-420.
6. Ciechanover A, Ben-Saadon R. (2004). N-terminal ubiquitination: more protein substrates join in. Trends Cell Biol 14: 103-106.
7. Doyon Y, Selleck W, Lane WS, Tan S, Cote J. (2004). Structural and functional conservation of the NuA4 histone acetyltransferase complex from yeast to humans. Mol Cell Biol 24: 1884-1896.
8. Fadlelmola FM, Zhou M, de Leeuw RJ, Dosanjh NS, Harmer K, Huntsman D et al. (2008). Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin lymphoma and anaplastic large cell lymphoma cell lines. Mol Cancer 7: 2.
9. Frescas D, Pagano M. (2008). Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8: 438-449.
10. Garate M, Campos EI, Bush JA, Xiao H, Li G. (2007). Phosphoryla-tion of the tumor suppressor p33(ING1b) at Ser-126 influences its protein stability and proliferation of melanoma cells. FASEB J 21: 3705-3716.
11. Garate M, Wong RP, Campos EI, Wang Y, Li G. (2008). NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33(ING1b). EMBO Rep 9: 576-581.
12. Goldberg AL. (2007). Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35: 12-17.
13. Gong W, Russell M, Suzuki K, Riabowol K. (2006). Subcellular targeting of p33ING1b by phosphorylation-dependent 14-3-3 binding regulates p21WAF1 expression. Mol Cell Biol 26: 2947-2954.
14. Gunduz M, Beder LB, Gunduz E, Nagatsuka H, Fukushima K, Pehlivan D et al. (2008). Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci 99: 531-538.
15. Gunduz M, Ouchida M, Fukushima K, Ito S, Jitsumori Y, Nakashima T et al. (2002). Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 21: 4462-4470.
16. He GH, Helbing CC, Wagner MJ, Sensen CW, Riabowol K. (2005). Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol 22: 104-116.
17. Hershko DD. (2008). Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 112: 1415-1424.
18. Inoue T, Geyer RK, Howard D, Yu ZK, Maki CG. (2001). MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem 276: 45255-45260.
19. Katagiri Y, Hozumi Y, Kondo S. (2006). Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J Dermatol Sci 42: 215-224.
20. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. (2004). N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 18: 1862-1874.
21. Li J, Martinka M, Li G. (2008). Role of ING4 in human melanoma cell migration, invasion, and patient survival. Carcinogenesis 29: 1373-1379.
22. Li Q, Murphy M, Ross J, Sheehan C, Carlson JA. (2004). Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol 31: 633-642.
23. Lu F, Dai DL, Martinka M, Ho V, Li G. (2006). Nuclear ING2 expression is reduced in human cutaneous melanomas. Br J Cancer 95: 80-86.
24. Mani A, Gelmann EP. (2005). The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789.
25. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K et al. (2002). Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 62: 3819-3825.
26. Nagashima M, Shiseki M, Pedeux RM, Okamura S, Kitahama-Shiseki M, Miura K et al. (2003). A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene 22: 343-350.
27. Nalepa G, Rolfe M, Harper JW. (2006). Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 5: 596-613.
28. Nandi D, Tahiliani P, Kumar A, Chandu D. (2006). The ubiquitinproteasome system. J Biosci 31: 137-155.
29. Newton K, Vucic D. (2007). Ubiquitin ligases in cancer: ushers for degradation. Cancer Invest 25: 502-513.
30. Ng KC, Campos EI, Martinka M, Li G. (2004). XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol 123: 1127-1134.
31. Nouman GS, Anderson JJ, Mathers ME, Leonard N, Crosier S, Lunec J et al. (2002). Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions. Histopathology 40: 360-366.
32. Schwechheimer C, Calderon Villalobos LI. (2004). Cullin-containing E3 ubiquitin ligases in plant development. Curr Opin Plant Biol 7: 677-686.
33. Shah IM, Di Napoli M. (2007). The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases. Cardiovasc Hematol Disord Drug Targets 7: 250-273.
34. Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M. (2006). Significance of skp2 expression in primary breast cancer. Clin Cancer Res 12: 1215-1220.
35. Sumimoto H, Hirata K, Yamagata S, Miyoshi H, Miyagishi M, Taira K et al. (2006). Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int J Cancer 118: 472-476.
36. Tsai KW, Tseng HC, Lin WC. (2008). Two wobble-splicing events affect ING4 protein subnuclear localization and degradation. Exp Cell Res 314: 3130-3141.
37. von Mikecz A. (2006). The nuclear ubiquitin-proteasome system. J Cell Sci 119: 1977-1984.
38. Wang Y, Dai DL, Martinka M, Li G. (2007). Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin Cancer Res 13: 4111-4116.
39. Wang Y, Li G. (2006). ING3 promotes UV-induced apoptosis via Fas/caspase-8 pathway in melanoma cells. J Biol Chem 281: 11887-11893.
40. Woenckhaus C, Maile S, Uffmann S, Bansemir M, Dittberner T, Poetsch M et al. (2005). Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol Histopathol 20: 501-508.
41. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM et al. (2002). Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 8: 3419-3426.
42. Yokoi S, Yasui K, Mori M, Iizasa T, Fujisawa T, Inazawa J. (2004). Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes. Am J Pathol 165: 175-180.
43. Zetter BR, Mangold U. (2005). Ubiquitin-independent degradation and its implication in cancer. Future Oncol 1: 567-570.